

NCI Cancer Integrative Medicine Research Grantee Conference

Dec 10-11, 2024.

Virtual and Open to Public.

Event Website:

<https://events.cancer.gov/nci/integrative-medicine>

Event Registration:

- **Day 1, Dec 10, 2024: 9:30am-5:30pm ET**
<https://cbiit.webex.com/weblink/register/r069a42aa7a7127ffa898f61f8eee4997>
- **Day 2, Dec 11, 2024: 10:30am-4:00pm ET**
<https://cbiit.webex.com/weblink/register/raaf6f8f89fe04c1a29a205713e1048f8>

Event Contact: Dan Xi, PhD, event Chair, NCI, xida@mail.nih.gov

Event IT Log-in Contact: Alison Caro Caro, NCI, alisoncaro.caro@nih.gov

Objectives:

- (1) **Grantsmanship:** to provide opportunities for learning grantsmanship, tools, and resources from the NCI/NIH, and for NCI program staff to hear about grantee needs and challenges.
- (2) **Research:** to highlight the NCI/NIH funded cancer-related complementary and integrative medicine research and identify gaps or needs for mechanistic, translational and clinical research, and technology to advancing precision integrative oncology across cancer continuum.

Agenda

Dec 10, 2024, Day 1

<u>9:30-9:45am</u>	<u>Welcome Opening and Introduction Conference Objectives</u> <ul style="list-style-type: none">▪ Dan Xi, PhD, Program Director, event Chair, DCTD, NCI▪ Jeffrey White, MD, Director, Office of Cancer Complementary and Alternative Medicine, DCTD, NCI▪ Emily Tonorezos, MD, MPH, Director, Office of Cancer Survivorship, DCCPS, NCI
<u>9:45-10:00am</u>	<u>NCI Cancer Complementary and Integrative Medicine Funding Portfolio Analysis</u> Dan Xi, PhD, Program Director, NCI
<u>10:00am-12:00pm</u>	<u>Session 1: Grantsmanship: grant review, policy and funding mechanism</u> <i>(Moderators: Dan Xi and Scott Chen)</i>
10:00-11:00am	Grant Review (DEA, R15, P01, SEP, ESI): Scott Chen, PhD; Biman Paria, PhD; Klaus Piontek. PhD.
11:00-11:30am	Funding Opportunities (Program Directors): Nancy Emenaker, PhD, DCP (NOSI: NOT-CA-24-074); Hubbard Leah, PhD, DCTD (DCTD Spore Program P50); Dan Xi, PhD, DCTD (PAR-25-081 etc.).
11:30-11:50am	New Grant Review Criteria and Data Sharing Policy (DEA): David Ransom. PhD.
11:50am-12:00pm	QA/Discussion

12:00-12:30pm, 30min Lunch Break

<u>12:30-1:30pm</u>	<u>Session 2: Research Methodology and Data Analysis</u> <i>(Moderator: Dan Xi)</i>
12:30-12:45pm	Natural product research methodology (U19) Jim (James) Simon, PhD, Rutgers University
12:45-1:00pm	Natural product preclinical research to clinical trial (Mushroom trial) (R01) Shiuan Chen, PhD, and Xiaoqiang Wang, MD, PhD, City of Hope
1:00-1:15pm	Statistics and trial design Jong-Hyeon Jeong, PhD, DCTD, NCI
1:15-1:30pm	Discussion
	1:30-1:35pm, 5 min Break
<u>1:35-1:55pm</u>	<u>Establishing an Integrative Oncology Services (R13)</u> Santosh Rao, MD, University Hospitals
1:55-2:00pm	Panel Discussion (Moderator: Dan Xi): Ting Bao, MD, Dana-Farber Cancer Center (R13, R01)
<u>2:00-3:35pm</u>	<u>Session 3: Translational and Clinical Cancer Research-Treatment and Toxicity</u> <i>(Moderator: Dan Xi)</i>
2:00-2:15pm	Circadian clock and cancer therapy (R01) Satchin Panda, PhD, Salk Institute for Biological Studies
2:15-2:30pm	Trial: exercise and immunotherapy (R01) Richard Simpson, PhD, The University of Arizona
2:30-2:45pm	Trial: coffee, colon cancer therapy and microbiome (R01) Mingyang Song, PhD, Harvard T.H. Chan School of Public Health
2:45-3:00pm	Trial: keto diet and glioblastoma multiforme (R01) Jethro Hu, MD, Cedars-Sinai
3:00-3:15pm	Natural Phenolics for Alleviating Irinotecan-induced Severe Diarrhea (R01-Chinese Herbal trial) Ming Hu, PhD, University of Houston
3:15-3:35pm	Discussion
	3:35-3:40pm, 5 min Break
<u>3:40-4:25pm</u>	<u>Session 4: Cancer Prevention-Clinical Research</u> <i>(Moderators: Gabriela Riscuta and Nancy Ememaker)</i>
3:40-3:55pm	Kava and lung cancer (R03) Chengguo Xing, PhD, University of Florida
3:55-4:10pm	Role of E-FABP in fish oil-induced immunoregulation (R01) Bing Li, PhD, University of Iowa
4:10-4:25pm	Discussion
	4:25-4:30pm, 5 min Break
<u>4:30-5:30pm</u>	<u>Session 5: NCI Clinical Trial Network and Resources</u> <i>(Moderators: Brennan Streck and Dan Xi)</i>
4:30-4:45pm	NCI NCORP resource Marge Good, RN, MPH, Program Director, DCP, NCI
4:45-5:00pm	Trial: green tea and prostate cancer (R01) Nagi Kumar, PhD, Moffitt Cancer Center
5:00-5:15pm	Trial: nutrient and surgery outcome (R37) (pre-recording) Jill Hamilton-Reeves, PhD, RD, University of Kansas Medical Center
5:15-5:30pm	Discussion
<u>5:30pm</u>	<u>Day 1 Adjourn</u>

Dec 11, 2024, Day 2

10:30-10:35am

Welcome Day 2

Dan Xi, PhD, DCTD, NCI

10:35-11:00am

Overview: Cancer Survivorship and Symptom Management Research Methodology

Emily Tonorezos, MD, MPH, Director, Office of Cancer Survivorship, DCCPS, NCI

11:00am-12:30pm

Session 6: Cancer Symptom Management (1)

(Moderators: Emily Tonorezos and Rachel Altshuler)

11:00-11:15am

Trials: precision acupuncture for insomnia & cognition (R01) (pre-recording)

Jun Mao, MD, Memorial Sloan Kettering Cancer Center

11:15-11:30am

Trial: acupuncture for nocturia in prostate cancer survivors (K08)

Kevin Liou, MD, Memorial Sloan Kettering Cancer Center

11:30-11:45am

Trial: auricular point acupressure for chemotherapy-induced neuropathy (R01)

Nada Lukkahatai, PhD, MSN, RN, FAAN, Johns Hopkins School of Nursing

11:45am-12:00pm

Trials: acupuncture neuropathy trial and yoga neuropathy trial (R01)

Ting Bao, MD, Dana-Farber Cancer Center

12:00-12:15pm

Trial: creatine supplementation and resistance training (R01)

Adriana Coletta, PhD, RD, University of Utah

12:15-12:30pm

Discussion

12:30-1:00pm, 30 min Lunch Break

1:00-2:15pm

Session 7: Cancer Symptom Management (2)

(Moderators: Catherine Schweppe and Emily Tonorezos)

1:00-1:15pm

Music intervention (R61)

Teresa Lesiuk, PhD, University of Miami

1:15-1:30pm

Mindfulness-Based mobile (R21)

Andrea Enzinger, MD, Dana-Farber Cancer Center

1:30-1:45pm

Mind-body intervention (R01)

Julienne Bower, PhD, University of California Los Angeles

1:45-2:00pm

Evaluating the efficacy of a mindfulness-based intervention for caregivers of allogeneic hematopoietic stem cell patients (R01) Christine Vinci, PhD, Moffitt Cancer Center

2:00-2:15pm

Discussion

2:15-2:20pm, 5 min Break

2:20-3:00pm

Session 8: Disparities Cancer Research

(Moderator: Dan Xi and Anil Wali)

2:20-2:35pm

Writing to heal (R01)

Qian Lu, PhD, University of Texas MD Anderson Cancer Center

2:35-2:50pm

Polyunsaturated fatty acids and breast cancer (K01)

Humberto Parada, PhD, San Diego State University

2:50-3:00pm

Discussion

3:00-3:30pm

Session 9: Final Discussion and Funding Opportunities

(Moderators: Dan Xi and Emily Tonorezos)

Speakers; Babara Sorkin (ODS/OD/NIH-NOFO); Patricia Weber, DrPH (NCI-SBIR); other NCI staff

3:30pm

Day 2 Adjourn

References and Resources:

- Xi D, Bao T, Chen Q, et al. State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report. J Natl Cancer Inst Monogr. 2017 Nov;2017(52):003. PMID: [PMC6061228](https://pubmed.ncbi.nlm.nih.gov/36061228/)
- NCI Integrative Medicine Education: <https://www.cancer.gov/grants-training/training/resources-trainees/courses-fellowships/integrative-medicine>
- About NCI: <https://www.cancer.gov/about-nci>
- National Cancer Plan: <https://nationalcancerplan.cancer.gov/>
- National Center for Complementary and Integrative Health: <https://www.nccih.nih.gov/>
- NIH Office of Dietary Supplement, Office of the Director: <https://ods.od.nih.gov/>
- [Research Portfolio Online Reporting Tools \(RePORT\)](#)
- [NIH Grants and Funding](#)
- [ClinicalTrials.gov](#)
- NCI grants and Training, and Examples of Relevant NCI NOFOs:
 - *Grants and Training:* <https://www.cancer.gov/grants-training>
 - *PAR-25-078: NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)* <https://grants.nih.gov/grants/guide/pa-files/PAR-25-078.html>
 - *PAR-25-139 : NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)* <https://grants.nih.gov/grants/guide/pa-files/PAR-25-139.html#:~:text=The%20R21%20mechanism%20is%20intended,conceptual%20stages%20of%20these%20projects.>
 - *PAR-25-081: National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)* <https://grants.nih.gov/grants/guide/pa-files/PAR-25-081.html>
 - *PAR-25-167: Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)* <https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html>
 - *NOT-CA-24-074: Notice of Special Interest (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research* <https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-074.html>

NCI Cancer Complementary and Integrative Medicine Working Group: Grantee Meeting Planning Committee (Extramural Program Directors/Officers)

- DCTD, NCI: Dan Xi, PhD, Chair
- DCP, NCI: Rachel Altshuler, PhD; Nancy Emenaker, PhD; Marge Good, RN, MPH; Gabriela Riscuta, MD, CNS; Catherine Schweppe, PhD; Brennan Streck, PhD, RN.
- DCCPS, NCI: Emily Tonorezos, MD, MPH.
- CCHE, NCI: Anil Wali, PhD
- NIH OD/ODS: Babara Sorokin, PhD

NCI: National Cancer Institute
NIH: National Institutes of Health
CCHE: Center for Cancer Health Equity
DCCPS: Division of Cancer Control and Population Sciences
DCP: Division of Cancer Prevention
DCTD: Division of Cancer Treatment and Diagnosis
DEA: Division of Extramural Activities
ODS/OD, NIH: Office of Dietary Supplement, Office of the Director, NIH